A Double‐blind Randomized Clinical Trial Evaluating the Analgesic Efficacy of Ketorolac versus Butorphanol for Patients with Suspected Biliary Colic in the Emergency Department

Olsen, Jon; McGrath, Norine A.; Schwarz, Dana G.; Cutcliffe, Brian; Stern, Judith M.

doi:10.1111/j.1553-2712.2008.00178.x

Cited by 22 publications

(14 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This formulation could potentially be used in the future to treat circumscribed pruritus and thus avoid systemic side-effects. Adverse effects of butorphanol are, for example, dizziness, sedation and nausea (64,74). As with other morphine-like agents, respiratory depression can occur that is reversible in healthy subjects with moderate doses (up to 0.8 mg) of naloxone (64).…”

Section: Butorphanolmentioning

confidence: 99%

Systemic Kappa Opioid Receptor Agonists in the Treatment of Chronic Pruritus: A Literature Review

Phan¹,

Lotts²,

Antal³

et al. 2012

Acta Derm Venerol

124

View full text Add to dashboard Cite

Chronic pruritus is frequently refractory to currently available treatments. Studies suggest that pruritus may arise from an imbalance of the mu- and kappa-opioid receptor system activity in either the skin or the central nervous system. Stimulation of kappa-opioid receptors by their agonists inhibits pruritus in both animals and humans. The antipruritic effect of kappa-opioid receptors agonists can currently be assumed to be related to their binding to kappa-opioid receptors on keratinocytes and cutaneous and/or central itch neurones. To date, several case reports and 2 controlled trials have demonstrated a beneficial effect of systemic kappa-opioid receptor agonists in the treatment of uraemic pruritus, prurigo nodularis, paraneoplastic and cholestatic pruritus. Nalfurafine hydrochloride (Remitch(®)), a selective kappa-opioid receptor agonist, is approved for the treatment of chronic pruritus in Japan. The aim of this review is to provide an overview of the promising role of kappa- opioid receptors and their agonist in the pathophysiology and treatment of pruritus.

show abstract

Section: Butorphanolmentioning

confidence: 99%

Systemic Kappa Opioid Receptor Agonists in the Treatment of Chronic Pruritus: A Literature Review

Phan¹,

Lotts²,

Antal³

et al. 2012

Acta Derm Venerol

124

View full text Add to dashboard Cite

show abstract

“…However, a major systematic review was not selectively focused on visceral pain [243]. Multiple studies have found that NSAIDs are effective for biliary colic and are as effective as opioids with fewer side effects [244–247]. One of the mechanisms by which NSAIDs work in renal or biliary colic may involve acetylcholine blockade.…”

Section: Pharmacologic Management Of Visceral Painmentioning

confidence: 99%

Drug Management of Visceral Pain: Concepts from Basic Research

Davis

2012

Pain Research and Treatment

View full text Add to dashboard Cite

Visceral pain is experienced by 40% of the population, and 28% of cancer patients suffer from pain arising from intra- abdominal metastasis or from treatment. Neuroanatomy of visceral nociception and neurotransmitters, receptors, and ion channels that modulate visceral pain are qualitatively or quantitatively different from those that modulate somatic and neuropathic pain. Visceral pain should be recognized as distinct pain phenotype. TRPV1, Na 1.8, and ASIC3 ion channels and peripheral kappa opioid receptors are important mediators of visceral pain. Mu agonists, gabapentinoids, and GABAB agonists reduce pain by binding to central receptors and channels. Combinations of analgesics and adjuvants in animal models have supra-additive antinociception and should be considered in clinical trials. This paper will discuss the neuroanatomy, receptors, ion channels, and neurotransmitters important to visceral pain and provide a basic science rationale for analgesic trials and management.

show abstract

“…Olsen et al[9] carried out a prospective randomized controlled trial comparing the efficacy of ketorolac vs butorphanol for patients with suspected biliary colic in the emergency department. This was a compact study with a definite aim (though limited by a small sample size) which concluded that both agents can be considered reasonable options in patients presenting with biliary colic, especially those with a need for further investigations.…”

Section: Resultsmentioning

confidence: 99%

Acute pain management in symptomatic cholelithiasis

Masudi

Capitelli-McMahon

Anwar

2016

WJGS

View full text Add to dashboard Cite

AIMTo review the evidence for the use of different non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of biliary colic.METHODSThe strategies employed included an extensive literature review for articles and studies related to biliary colic from electronic databases including PubMed, Science Direct, Wiley Inter Science, Medline and Cochrane from last 15 years. Keywords: “Biliary colic”, “management of biliary colic”, “non-steroidal anti-inflammatory drugs”, “cholelithiasis” and “biliary colic management”. Six randomized control trials, 1 non-randomized trial and 1 meta-analysis were included in this review. The outcomes of these studies and their significance have been reviewed in this paper.RESULTSCurrent evidence suggests there are no set protocols for biliary colic pain management. NSAIDs are potent in the management of biliary colic, not only in terms of symptom control but in disease progression as well. Apart from the studies on diclofenac and ketorolac, there are studies which have shown that intravenous tenoxicam and injectable flurbiprofen are equally effective in managing biliary colic. The efficacy of NSAIDs is superior in terms of lower number of doses and longer duration of action in comparison to other analgesic agents.CONCLUSIONThis literature review has found that NSAIDs are safe and effective for pain control in biliary colic, and reduce the likelihood of further complications.

show abstract

A Double‐blind Randomized Clinical Trial Evaluating the Analgesic Efficacy of Ketorolac versus Butorphanol for Patients with Suspected Biliary Colic in the Emergency Department

Abstract: Objectives: Patients presenting to the emergency department (ED) with suspected biliary colic often require intravenous (IV) analgesia. The choice of IV analgesia typically includes opioids and ketorolac.

Cited by 22 publications

References 11 publications

Systemic Kappa Opioid Receptor Agonists in the Treatment of Chronic Pruritus: A Literature Review

Systemic Kappa Opioid Receptor Agonists in the Treatment of Chronic Pruritus: A Literature Review

Drug Management of Visceral Pain: Concepts from Basic Research

Acute pain management in symptomatic cholelithiasis

Contact Info

Product

Resources

About